Bristol-Myers Squibb (BMY) Tops Q2 EPS by 17c; Boosts FY15 EPS Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Bristol-Myers Squibb (BMY) Tops Q2 EPS by 17c; Boosts FY15 EPS Outlook

Bristol-Myers Squibb Reports Second Quarter Financial Results

July 23, 2015 7:30 AM EDT

Increases Revenues 7% to $4.2 Billion Posts Second Quarter GAAP Loss Per Share of $0.08 and Non-GAAP EPS of $0.53 Achieves Important Regulatory and Clinical Milestones for Opdivo (nivolumab) Approvals in Europe for Metastatic Melanoma and Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Validation in Europe of Applications for Opdivo in Non-Squamous NSCLC and in Combination with Yervoy for Metastatic Melanoma Early Stop of CheckMate -025, a Phase 3 Study Evaluating in Patients with Renal Cell Carcinoma, After... More